Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Jessica S. Crystal"'
Autor:
Jeffrey S. Johnson, Farin Amersi, Armando E. Giuliano, Alice Chung, Jessica S. Crystal, Reva Basho, Jamie Rand, Sungjin Kim
Publikováno v:
Breast Cancer Research and Treatment. 184:63-74
There is controversy regarding the survival benefit of endocrine therapy (ET) in elderly patients with early invasive hormone receptor-positive (HR+) breast cancer. In this study, we characterize a single institution’s practice patterns using adjuv
Autor:
Jun Gong, Andrew Eugene Hendifar, Jessica S. Crystal, Nicholas Manguso, Alexandra Gangi, Richard Tuli, Shirley C Paski
Publikováno v:
Annals of Surgical Oncology. 27:4525-4532
Management of metastatic midgut neuroendocrine tumors (MNET) remains controversial. The benefits of resecting the primary tumor are not clear and advocated only for select patients. This study aimed to determine whether resection of the primary MNET
Autor:
Andrew E. Rosenberg, Celeste Chitters, Emily L. Ryon, Sina Yadegarynia, Gina Z. D'Amato, Jessica S. Crystal, Raphael Yechieli, Neha Goel, Susan B. Kesmodel, Jonathan C. Trent, Joshua P. Kronenfeld
Publikováno v:
Cancers
Volume 13
Issue 15
Cancers, Vol 13, Iss 3814, p 3814 (2021)
Volume 13
Issue 15
Cancers, Vol 13, Iss 3814, p 3814 (2021)
Simple Summary Primary angiosarcoma of the breast (PAS) and radiation-associated angiosarcoma of the breast (RAAS) are rare sarcomas that affect the inner lining of blood vessels in the breast with incidences of 0.05% and 0.02%, respectively. This st
Autor:
Harshini Chinnasamy, Todd D. Prickett, Li Jia, Paul F. Robbins, Isaac R. Kriley, Yasmine Assadipour, Steven A. Rosenberg, Steven A. Feldman, Stephanie L. Goff, Jared J. Gartner, Nikolaos Zacharakis, Jessica S. Crystal, John R. Wunderlich, Yong-Chen Lu, Robert Somerville, Mary A. Black, Lily Lu, Hui Xu, Zhili Zheng
Publikováno v:
Clinical Cancer Research. 23:4347-4353
Purpose: The administration of autologous tumor-infiltrating lymphocytes (TILs) can mediate durable tumor regressions in patients with melanoma likely based on the recognition of immunogenic somatic mutations expressed by the cancer. There are limite
Autor:
Maria R. Parkhurst, Anna Pasetto, Alena Gros, Jessica S. Crystal, Steven A. Rosenberg, Todd D. Prickett, Paul F. Robbins
Publikováno v:
Clinical Cancer Research. 23:2491-2505
Purpose: The adoptive transfer of lymphocytes genetically modified to express tumor reactive T-cell receptors (TCR) can mediate tumor regression. Some tumor-infiltrating lymphocytes (TIL) recognize somatic mutations expressed only in the patient's tu
Autor:
John R. Wunderlich, Paul F. Robbins, Anna Pasetto, Li Jia, Mona El-Gamil, Gal Cafri, Maria R. Parkhurst, Eric Tran, Yong F. Li, Lien T. Ngo, Winifred Lo, Robert Somerville, Mojgan Ahmadzadeh, Jessica S. Crystal, Todd D. Prickett, Gabriel Ivey, Satyajit Ray, Frank J. Lowery, Rami Yossef, Abraham Sachs, Steven A. Rosenberg, Almin Lalani, Scott Kivitz, Eric M. Groh, Drew C. Deniger, Parisa Malekzadeh, Stephanie L. Goff, Jared J. Gartner
Publikováno v:
Cancer discovery. 9(8)
Immunotherapies can mediate regression of human tumors with high mutation rates, but responses are rarely observed in patients with common epithelial cancers. This raises the question of whether patients with these common cancers harbor T lymphocytes
Autor:
Steven C Tizio, Jessica S. Crystal, Kristin Korderas, Min Zheng, David Schwartzberg, Glenn Parker
Publikováno v:
Case Reports in Surgery
Case Reports in Surgery, Vol 2018 (2018)
Case Reports in Surgery, Vol 2018 (2018)
Primary leiomyosarcomas (LMS) of the colon are rare and aggressive neoplasms and have been infrequently reported in the literature. These tumors are more aggressive and have poorer prognoses than adenocarcinoma of the colon and are often mistaken as
Autor:
Mona El-Gamil, Kasia Trebska-Mcgowan, Jessica S. Crystal, Alena Gros, Jared J. Gartner, Yong F. Li, Todd D. Prickett, Rong Wang, Maria R. Parkhurst, Paul F. Robbins, Cyrille J. Cohen, Anna Pasetto, Steven A. Rosenberg, Xin Yao
Immunotherapy treatment of patients with metastatic cancer has assumed a prominent role in the clinic. Durable complete response rates of 20% to 25% are achieved in patients with metastatic melanoma following adoptive cell transfer of T cells derived
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19efe2a29b55440eab521a9e872e0387
https://europepmc.org/articles/PMC4970903/
https://europepmc.org/articles/PMC4970903/